Research programme: anti CD3 and anti CD20 bispecific T cell engagers - Adagene
Alternative Names: CD20xCD3 SAFE bsAb - Adagene; CD20xCD3 SAFE-bispecific antibodies - Adagene; CD20xCD3 SAFE-bsAbs - Adagene; CD20XCD3 T cell engagers - Adagene; CD3XCD20 bispecific T-cell engager programme - Adagene; SAFEbody CD20xCD3 BsAb T-cell Engager Programme - AdageneLatest Information Update: 20 Sep 2021
At a glance
- Originator Adagene
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Sep 2021 Anti CD3 and anti CD20 bispecific T cell engagers - Adagene is available for licensing as of 20 Sep 2021. https://www.adagene.com/contact/
- 26 Aug 2021 Adagene announces intention to file IND application for Cancer in 2022
- 29 Jul 2021 Adagene has patents pending for bispecific T cell engager targeting CD3 worldwide